Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

被引:27
|
作者
Kuwata, Hitoshi [1 ,2 ]
Yabe, Daisuke [1 ,3 ,4 ]
Murotani, Kenta [5 ]
Fujiwara, Yuuka [1 ]
Haraguchi, Takuya [1 ,2 ,3 ]
Kubota, Sodai [1 ,3 ]
Kubota-Okamoto, Saki [1 ,3 ]
Usui, Ryota [1 ,2 ]
Ishitobi, Minori [2 ]
Yamazaki, Yuji [1 ,2 ]
Hamamoto, Yoshiyuki [1 ,2 ]
Kurose, Takeshi [1 ,6 ]
Seino, Yusuke [7 ]
Yamada, Yuichiro [1 ,2 ]
Seino, Yutaka [1 ,2 ]
机构
[1] Kansai Elect Power Med Res Inst, Yutaka Seino Distinguished Ctr Diabet Res, Kobe, Hyogo, Japan
[2] Kansai Elect Power Hosp, Ctr Diabet Endocrinol & Metab, Osaka, Japan
[3] Gifu Univ, Grad Sch Med, Dept Diabet Endocrinol & Metab, Gifu, Japan
[4] Kobe Univ, Grad Sch Med, Div Mol & Metab Med, Kobe, Hyogo, Japan
[5] Kurume Univ, Grad Sch Med, Biostat Ctr, Kurume, Fukuoka, Japan
[6] Nakanoshima Clin, Osaka, Japan
[7] Fujita Hlth Univ, Dept Endocrinol & Metab, Toyoake, Aichi, Japan
关键词
Gastric emptying; GLP-1 receptor agonist; islet hormones; OPEN-LABEL; INCRETIN SECRETION; LIRAGLUTIDE; LIXISENATIDE; GLP-1; STIMULATION; GLUCOSE; SAFETY; GIP;
D O I
10.1111/jdi.13598
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Introduction Differences in the glucose-lowering mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. Materials and Methods A single-arm, prospective, observational study was conducted to evaluate the effects of various GLP-1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP-1RA initiation. Effects on postprandial secretions of glucose-dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. Results Eighteen subjects with type 2 diabetes received one of three GLP-1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12-week administration of all of the GLP-1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP-1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP-1RAs. Conclusions All of the GLP-1RAs were found to improve HbA1c in a 12-week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose-lowering effects and body weight reduction were observed.
引用
收藏
页码:2162 / 2171
页数:10
相关论文
共 50 条
  • [31] Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
    Sarraju, Ashish
    Kim, Sun H.
    Knowles, Joshua W.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (02) : 1 - 8
  • [32] Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
    Chilton, Robert J.
    JOURNAL OF DIABETES & METABOLISM, 2015, 6 (01)
  • [33] Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
    Berlie, Helen
    Hurren, Kathryn M.
    Pinelli, Nicole R.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2012, 5 : 165 - 174
  • [34] It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
    Oberle, Megan M.
    Kelly, Aaron S.
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [35] Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide
    MacIsaac, Richard J.
    FUTURE CARDIOLOGY, 2021, 17 (03) : 459 - 473
  • [36] NEPHROPROTECTIVE POTENTIAL OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
    Shamhalova, Minara S.
    Sklyanik, Igor A.
    Shestakova, Marina V.
    DIABETES MELLITUS, 2020, 23 (01): : 56 - 64
  • [37] Renal protection with glucagon-like peptide-1 receptor agonists
    Vitale, Martina
    Haxhi, Jonida
    Cirrito, Tiziana
    Pugliese, Giuseppe
    CURRENT OPINION IN PHARMACOLOGY, 2020, 54 : 91 - 101
  • [38] Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects
    Sloan, Lance A.
    JOURNAL OF DIABETES, 2019, 11 (12) : 938 - 948
  • [39] Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
    Ja'arah, Daria
    Al Zoubi, Mazhar Salim
    Abdelhady, Gamal
    Rabi, Firas
    Tambuwala, Murtaza M.
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2021, 14
  • [40] Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
    Lovshin, Julie A.
    CANADIAN JOURNAL OF DIABETES, 2017, 41 (05) : 524 - 535